The Leu7Pro polymorphism of the signal peptide of neuropeptide Y (NPY) gene is associated with increased levels of inflammatory markers preceding vascular complications in patients with type 2 diabetes

Microvascular Research

Volumn 80, Issue 3, 2010, Pages 433-439

  Jaakkola, U ^a   Kakko, T ^a   Seppala H ^b   Vainio Jylha E ^c   Vahlberg, T ^a   Raitakari, O T ^a,c   Kallio, J ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU CITY HOSPITAL   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Diabetes; E selectin; Endothelial function; Inflammation; Leu7Pro polymorphism; Microalbuminuria; NPY

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CELL DNA; CREATININE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INSULIN; NEUROPEPTIDE Y; NITRATE; SERUM AMYLOID P;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC ANGIOPATHY; DIABETIC PATIENT; ECHOGRAPHY; ENDOTHELIUM; FEMALE; FOLLOW UP; GENE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; MALE; MUTATIONAL ANALYSIS; NEUROPEPTIDE Y GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; VASODILATATION;

AGED; ALBUMINURIA; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; E-SELECTIN; FEMALE; FINLAND; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; LINEAR MODELS; LOGISTIC MODELS; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; NEUROPEPTIDE Y; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROTEIN SORTING SIGNALS; RISK ASSESSMENT; RISK FACTORS; SERUM AMYLOID P-COMPONENT; SEX FACTORS; TIME FACTORS; UP-REGULATION; VASODILATION;

EID: 78249286181     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2010.07.010     Document Type: Article

References (48)

1. Ardigo D., Franzini L., Valtuena S., Numeroso F., Piatti P.M., Monti L., et al. The increase in plasma PAI-1 associated with insulin resistance may be mediated by the presence of hepatic steatosis. Atherosclerosis 2010, 208:240-245.
2. Bansilal S., Farkouh M.E., Fuster V. Role of insulin resistance and hyperglycemia in the development of atherosclerosis. Am. J. Cardiol. 2007, 99:6B-14B.
3. Clarke J.G., Davies G.J., Kerwin R., Hackett D., Larkin S., Dawbarn D., et al. Coronary artery infusion of neuropeptide Y in patients with angina pectoris. Lancet 1987, 1:1057-1059.
4. Davies M.J., Gordon J.L., Gearing A.J., Pigott R., Woolf N., Katz D., et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J. Pathol. 1993, 171:223-229.
5. Di Carlo C., Di Spiezio Sardo A., Bifulco G., Tommaselli G.A., Guerra G., Rippa E., et al. Postmenopausal hypoestrogenism increases vasoconstrictor neuropeptides and decreases vasodilator neuropeptides content in arterial-wall autonomic terminations. Fertil. Steril. 2007, 88:95-99.
6. Ding B., Kull B., Liu Z., Mottagui-Tabar S., Thonberg H., Gu H.F., et al. Human neuropeptide Y signal peptide gain-of-function polymorphism is associated with increased body mass index: possible mode of function. Regul. Pept. 2005, 127:45-53.
7. Eschen O., Christensen J.H., Dethlefsen C., Schmidt E.B. Cellular adhesion molecules in healthy subjects: short term variations and relations to flow mediated dilation. Biomark. Insights 2008, 3:57-62.
8. Gerstein H.C., Mann J.F., Yi Q., Zinman B., Dinneen S.F., Hoogwerf B., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286:421-426.
9. Herder C., Schneitler S., Rathmann W., Haastert B., Schneitler H., Winkler H., et al. Low-grade inflammation, obesity, and insulin resistance in adolescents. J. Clin. Endocrinol. Metab. 2007, 92:4569-4574.
10. Ilveskoski E., Viiri L.E., Mikkelsson J., Porsti I., Lehtimaki T., Karhunen P.J. Neuropeptide Y signal peptide Pro7 substitution protects against coronary artery atherosclerosis: The Helsinki Sudden Death Study. Atherosclerosis 2008, 199:445-450.
11. Jaakkola U., Kuusela T., Jartti T., Pesonen U., Koulu M., Vahlberg T., et al. The Leu7Pro polymorphism of preproNPY is associated with decreased insulin secretion, delayed ghrelin suppression and increased cardiovascular responsiveness to norepinephrine during oral glucose-tolerance test. J. Clin. Endocrinol. Metab. 2005, 90:3646-3652.
12. Jaakkola U., Pesonen U., Vainio-Jylha E., Koulu M., Pollonen M., Kallio J. The Leu7Pro polymorphism of neuropeptide Y is associated with younger age of onset of type 2 diabetes mellitus and increased risk for nephropathy in subjects with diabetic retinopathy. Exp. Clin. Endocrinol. Diab. 2006, 114:147-152.
13. Jaakkola U., Koulu M., Karvonen M.K., Seppala H., Pesonen U., Vahlberg T., et al. Impact of the Leu7Pro polymorphism of preproNPY on diurnal NPY and hormone secretion in type 2 diabetes. Exp. Clin. Endocrinol. Diab. 2007, 115:281-286.
14. Jaakkola U., Kallio J., Heine R.J., Nijpels G., T'Hart L.M., Maassen J.A., et al. Neuropeptide Y polymorphism significantly magnifies diabetes and cardiovascular disease risk in obesity: the Hoorn Study. Eur. J. Clin. Nutr. 2009, 63:150.
15. Järvisalo M.J., Lehtimaki T., Raitakari O.T. Determinants of arterial nitrate-mediated dilatation in children: role of oxidized low-density lipoprotein, endothelial function, and carotid intima-media thickness. Circulation 2004, 109:2885-2889.
16. Jefferis B.J., Whincup P., Welsh P., Wannamethee G., Rumley A., Lennon L., et al. Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women. Atherosclerosis 2010, 208:557-563.
17. Jenny N.S., Arnold A.M., Kuller L.H., Tracy R.P., Psaty B.M. Serum amyloid P and cardiovascular disease in older men and women: results from the Cardiovascular Health Study. Arterioscler. Thromb. Vasc. Biol. 2007, 27:352-358.
18. Juhan-Vague I., Pyke S.D., Alessi M.C., Jespersen J., Haverkate F., Thompson S.G. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996, 94:2057-2063.
19. Kaipio K., Kallio J., Pesonen U. The effect of endogenous preproneuropeptide Y leucine 7 to proline 7 polymorphism on growth and apoptosis in primary cultured HUVECs. Biol. Chem. 2009, 390:899-905.
20. Kallio J., Pesonen U., Kaipio K., Karvonen M.K., Jaakkola U., Heinonen O.J., et al. Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans. FASEB J. 2001, 15:1242-1244.
21. Kallio J., Pesonen U., Jaakkola U., Karvonen M.K., Helenius H., Koulu M. Changes in diurnal sympathoadrenal balance and pituitary hormone secretion in subjects with Leu7Pro polymorphism in the prepro-neuropeptide Y. J. Clin. Endocrinol. Metab. 2003, 88:3278-3283.
22. Karvonen M.K., Pesonen U., Koulu M., Niskanen L., Laakso M., Rissanen A., et al. Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nat. Med. 1998, 4:1434-1437.
23. Karvonen M.K., Valkonen V.P., Lakka T.A., Salonen R., Koulu M., Pesonen U., et al. Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. Atherosclerosis 2001, 159:145-151.
24. Kobari M., Fukuuchi Y., Tomita M., Tanahashi N., Yamawaki T., Takeda H., et al. Transient cerebral vasodilatory effect of neuropeptide Y mediated by nitric oxide. Brain Res. Bull. 1993, 31:443-448.
25. Kos K., Harte A.L., James S., Snead D.R., O'Hare J.P., McTernan P.G., et al. Secretion of neuropeptide Y in human adipose tissue and its role in maintenance of adipose tissue mass. Am. J. Physiol. Endocrinol. Metab. 2007, 293:E1335-E1340.
26. Koulu M., Movafagh S., Tuohimaa J., Jaakkola U., Kallio J., Pesonen U., et al. Neuropeptide Y and Y2-receptor are involved in development of diabetic retinopathy and retinal neovascularization. Ann. Med. 2004, 36:232-240.
27. Lee E.W., Michalkiewicz M., Kitlinska J., Kalezic I., Switalska H., Yoo P., et al. Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J. Clin. Invest. 2003, 111:1853-1862.
28. Ma J., Nordman S., Mollsten A., Falhammar H., Brismar K., Dahlquist G., et al. Distribution of neuropeptide Y Leu7Pro polymorphism in patients with type 1 diabetes and diabetic nephropathy among Swedish and American populations. Eur. J. Endocrinol. 2007, 157:641-645.
29. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
30. McCulloch C.E. Generalized, Linear, and Mixed Models 2003, John Wiley & Sons, New York.
31. Meshkani R., Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin. Biochem. 2009, 42:1331-1346.
32. Mitchell G.C., Wang Q., Ramamoorthy P., Whim M.D. A common single nucleotide polymorphism alters the synthesis and secretion of neuropeptide Y. J. Neurosci. 2008, 28:14428-14434.
33. Nishiwaki Y., Yoshida M., Iwaguro H., Masuda H., Nitta N., Asahara T., et al. Endothelial E-selectin potentiates neovascularization via endothelial progenitor cell-dependent and -independent mechanisms. Arterioscler. Thromb. Vasc. Biol. 2007, 27:512-518.
34. Niskanen L., Karvonen M.K., Valve R., Koulu M., Pesonen U., Mercuri M., et al. Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with enhanced carotid atherosclerosis in elderly patients with type 2 diabetes and control subjects. J. Clin. Endocrinol. Metab. 2000, 85:2266-2269.
35. Niskanen L., Voutilainen-Kaunisto R., Terasvirta M., Karvonen M.K., Valve R., Pesonen U., et al. Leucine 7 to proline 7 polymorphism in the neuropeptide y gene is associated with retinopathy in type 2 diabetes. Exp. Clin. Endocrinol. Diab. 2000, 108:235-236.
36. Nordman S., Ding B., Ostenson C.G., Karvestedt L., Brismar K., Efendic S., et al. Leu7Pro polymorphism in the neuropeptide Y (NPY) gene is associated with impaired glucose tolerance and type 2 diabetes in Swedish men. Exp. Clin. Endocrinol. Diab. 2005, 113:282-287.
37. Pedrazzini T., Pralong F., Grouzmann E. Neuropeptide Y: the universal soldier. Cell. Mol. Life Sci. 2003, 60:350-377.
38. Pettersson-Fernholm K., Karvonen M.K., Kallio J., Forsblom C.M., Koulu M., Pesonen U., et al. Leucine 7 to proline 7 polymorphism in the preproneuropeptide Y is associated with proteinuria, coronary heart disease, and glycemic control in type 1 diabetic patients. Diab. Care 2004, 27:503-509.
39. Pitsavos C., Tampourlou M., Panagiotakos D.B., Skoumas Y., Chrysohoou C., Nomikos T., et al. Association between low-grade systemic inflammation and type 2 diabetes mellitus among men and women from the ATTICA study. Rev. Diab. Stud. 2007, 4:98-104.
40. Price D.T., Loscalzo J. Cellular adhesion molecules and atherogenesis. Am. J. Med. 1999, 107:85-97.
41. Ribatti D., Levi-Schaffer F., Kovanen P.T. Inflammatory angiogenesis in atherogenesis-a double-edged sword. Ann. Med. 2008, 40:606-621.
42. Rizvi A.A. Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: emerging concepts. Am. J. Med. Sci. 2009, 338:310-318.
43. Ruohonen S.T., Pesonen U., Moritz N., Kaipio K., Roytta M., Koulu M., et al. Transgenic mice overexpressing neuropeptide Y in noradrenergic neurons: a novel model of increased adiposity and impaired glucose tolerance. Diabetes 2008, 57:1517-1525.
44. Schindhelm R.K., van der Zwan L.P., Teerlink T., Scheffer P.G. Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification?. Clin. Chem. 2009, 55:1462-1470.
45. Slevin M., Matou-Nasri S., Turu M., Luque A., Rovira N., Badimon L., et al. Modified c-reactive protein is expressed by stroke neovessels and is a potent activator of angiogenesis in vitro. Brain Pathol. 2009, Jan 19. [Epub ahead of print].
46. Stewart C.R., Tseng A.A., Mok Y.F., Staples M.K., Schiesser C.H., Lawrence L.J., et al. Oxidation of low-density lipoproteins induces amyloid-like structures that are recognized by macrophages. Biochemistry 2005, 44:9108-9116.
47. Ukkola O., Kesäniemi Y.A. Leu7Pro polymorphism of PreproNPY associated with an increased risk for type II diabetes in middle-aged subjects. Eur. J. Clin. Nutr. 2007, 61:1102.
48. Zukowska-Grojec Z. Neuropeptide Y. A novel sympathetic stress hormone and more. Ann. NY Acad. Sci. 1995, 771:219-233.